Sofiva Genomics Co.,Ltd. (TPEX:6615)
33.65
0.00 (0.00%)
Aug 17, 2026, 10:58 AM CST
Sofiva Genomics Revenue
Sofiva Genomics had revenue of 97.07M TWD in the quarter ending June 30, 2026, a decrease of -3.59%. This brings the company's revenue in the last twelve months to 379.21M, down -6.67% year-over-year. In the year 2025, Sofiva Genomics had annual revenue of 385.71M, down -14.91%.
Revenue (ttm)
379.21M
Revenue Growth
-6.67%
P/S Ratio
1.92
Revenue / Employee
n/a
Employees
104
Market Cap
726.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 385.71M | -67.61M | -14.91% |
| Dec 31, 2024 | 453.31M | -13.49M | -2.89% |
| Dec 31, 2023 | 466.80M | -28.98M | -5.84% |
| Dec 31, 2022 | 495.78M | -12.64M | -2.49% |
| Dec 31, 2021 | 508.42M | 19.55M | 4.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.29B |
| DIVA Laboratories | 894.67M |
| Genetics Generation Advancement | 614.42M |
| Kim Forest Enterprise | 599.63M |
| Welgene Biotech | 398.92M |
| Pharmigene | 187.88M |
| Puriblood Medical | 80.54M |